Early trials found that both garadacimab and sebetralstat were safe when used in patients living with hereditary angioedema, ...

Surbhi Sidana, MD, MBBS, director of the Myeloma Disease Focused Group at Stanford University, provides a reintroduction to ...

Making clinical trials easier to find for clinicians and making protocols for entering clinical trials more lenient can help ...

Panelists discuss how combination therapies targeting different aspects of spinal muscular atrophy (SMA), such as myostatin ...

Panelists discuss how insurance challenges impact spinal muscular atrophy (SMA) care, with prior authorizations becoming more ...

Panelists discuss how riociguat targets the nitric oxide pathway and is approved for both Group 1 PAH and Group 4 chronic ...

The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across the globe, including in areas where the PURPOSE trials were conducted.

Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of ...

The FDA approval marks the first approval of a type of pre-exposure prophylaxis that would only require 2 treatments per year ...

This study highlights the vital role of caregivers in supporting women living with pulmonary arterial hypertension (PAH) and ...

Shorter venetoclax durations in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) yielded ...

High body mass index affects outcomes in acute lymphoblastic leukemia (ALL), highlighting the need for targeted interventions ...